Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.9700 (8.4%) ($6.3200 - $6.9900) on Tue. Sep. 10, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.96% (three month average) | RSI | 53 | Latest Price | $6.9700(8.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 2.5% a day on average for past five trading days. | Weekly Trend | TGTX advances 1.2% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.98% in a week (0% probabilities). VIXM(-39%) VXX(-37%) TLT(-8%) UUP(-7%) IGOV(-2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -1.98% (StdDev 3.96%) | Hourly BBV | 0 () | Intraday Trend | 7.6% | | | |
|
5 Day Moving Average | $6.49(7.4%) | 10 Day Moving Average | $6.33(10.11%) | 20 Day Moving Average | $6.46(7.89%) | To recent high | -22.5% | To recent low | 17.7% | Market Cap | $883m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |